www.jmscr.igmpublication.org Impact Factor 6.379

Index Copernicus Value: 71.58

ISSN (e)-2347-176x ISSN (p) 2455-0450

crossref DOI: https://dx.doi.org/10.18535/jmscr/v6i3.206



An Official Publication Of IGM Publication

## A Study on Soft Tissue Sarcomas (STS)

Authors

# Dr M. Kumara Senthil<sup>1</sup>, Dr G. Karthikeyan<sup>2</sup>, Dr N. Mohammed Niyamathullah<sup>3</sup>, Dr P.G. Ezhilan<sup>4</sup>

<sup>1</sup>Assistant Professor of Surgery, Thanjavur Medical College <sup>2</sup>Senior Asst Professor, Thanjavur Medical College <sup>3,4</sup>Resident, Thanjavur Medical College

#### **Abstract**

**Introduction:** STS constitute a significant challenge to the surgeon. They are rare tumor accounting for 1% of all malignancies. There are more than 20 histologic varieties. They are Aggressive neoplasms and have the propensity for early metastatic spread.

**Aim:** To study Age and sex incidence, Clinical presentation, various histology, Diagnostic modalities, various treatment modalities, Post-operative complication

Materials and method: Biopsy proven 40 cases of STS.

**Results:** Rare tumor in this region. Common in extremities. Peak incidence is 50years and above. 75% of patients had presented in advanced stage of disease. Surgery is the prime modality of treatment.

**Conclusion:** STS remains an ideal model for investigation of strategies designed to improve long term outcome. Multiple prognostic factors are being defined and the disease process is varied enough to provide a fertile field for treatment strategies.

**Keywords:** *Histology, Treatment modalities, Follow-up* 

#### Introduction

tissue neoplasms are defined heterogeneous group of tumours arising from PRIMITIVE MULTIPOTENT MESENCHYMAL cells, which undergo differentiation along one or more lines as the tumour evolves. There are wide variety of histopathological types each with varying biological behavior and a uniform character for haematogenous spread. soft tissue tumours often pose a diagnostic challenge to the pathologist, since many of the benign tumours are unencapsulated and show infiltrating margins, thus making it difficult to differentiate benign from malignant tumours. Although benign soft tissue neoplasms represent the commonest

neoplasm in human beings, their malignant counterparts accounts for only 0.8%-1 .0% of all malignant tumour adults, and 6-8% of those in children.

A variety of special procedures such as conventional special stains, immunohisto chemistry, solid tumour cytogenetics, electron microscopy, quantitative image analysis, and flow cytometry are now available to improve the diagnostic accuracy but none of them are much helpful to differentiate benign tumours from malignant neoplasms, till date. These tumours constitute a fertile field for clinicopathologists and pose a significant challenge to the treating surgeon.

## JMSCR Vol||06||Issue||03||Page1256-1259||March

#### Aim of Study

During the two years period from 2015-2017, cases of soft tissue tumors were followed and those which were histopathologically proved to be sarcomas were included in this study Various surgical procedures like Excision & biopsy, Wide excision and Radical procedureswere done. Soft tissue sarcomas present as a challenge to the surgeon. Hence the study for the following reasons-

- To study
- The age and sex incidence of soft tissue sarcomas.
- The clinical presentations (signs and symptoms)
- Diagnostic modalities used in evaluation of soft tissue sarcomas
- Various types of treatment offered
- Post-operative complications
- The various histology of soft tissue sarcomas

#### **Materials and Methods**

From Dec 2015 to Dec 2017 for a period of over 2 years, 43 cases were admitted in TMCH. All the 43 cases were studied in detail with clinical examination, Histopathological examination and Radiological investigations.

#### **Observation**

#### Sex

Sex	No of Patients	Percentage
Male	31	70%
Female	12	30%

#### Age

The peak incidence of these tumors was in the 5<sup>th</sup> decade of life.

The youngest patient in our study was a 2yr old male child with rhabdomyosarcoma whereas the oldest was a 75yr old male with fibrosarcoma.

Age Group	No 0f Patients	Percentage
< 10	3	7%
10 - 20	4	10%
20 -30	5	12%
30-40	9	20%
40-50	9	20%
50 And Above	13	30%

#### **Site Distribution**

The tumor site was predominantly in the extremities [80%]

Anatomical Site	No of Patients	Percentage
Lower Limb	22	54%
Upper Limb	12	26%
Abdomen	8	18%
Chest Wall	1	2%

### **Histopathology Distribution**

Out of 43 cases of soft tissue sarcomas, the most common were malignant fibrous histiocytoma and malignant neural tumours.

Histopathological Type	No of Patients	Percentage
Mfh	11	26%
Liposarcoma	7	16%
Ewingssarcoma	6	13%
Nerve Sheath Tumors	3	7%
Rhabdomyosarcoma	5	12%
Fibrosarcoma	9	20%
Lieomyosarcoma	1	3%
Synovial Sarcoma	1	3%

The increased incidence of malignant fibrous histiocytoma with a relative fall infibrosarcoma is probably due to the fact that were previously thought to be fibrosarcomas have now been diagnosed as malignant fibrous histiocytoma.

#### **Clinical Presentation**

The symptoms of prime importance for which the patients reported were painless swelling in 80% patients and painful swelling in 20% patients.

#### **Treatment**

Nature oftreatment	Percentage
Refused treatment	24%
Biopsy followed by RT & CT	30%
Debulking	9%
Wide excision with skin grafting	11%
Wide excision and CT & RT	26%

#### **Complications**

Out of 8 abdominal cases, we did excision for 4 cases, debulking for 2 cases. Of these 3 patients came with recurrence and reported with symptoms of abdominal pain, mass and lower limb edema.1 patient presented with features of subacute intestinal obstruction.1 patient with nerve sheath

## JMSCR Vol||06||Issue||03||Page1256-1259||March

tumor of popliteal region was operated and after 6 months he presented with paraplegia due to cord compression from metastasis. In extremity sarcomas operated, 4 cases presented with recurrences.

The observation derived from this study are:

- It is a rare tumor in this region with a marginal increase in incidence compared to the international literature.
- Extremity tumors account for the majority of sarcomas
- Peak incidence is between 50 years and above
- Male to female ratio is 2.3:1
- No predisposing factor is correlated with.
- Possesses no problem for physical examination and diagnosis, yet they are frequently diagnosed very late.
- 75% of patients had presented in advanced stage of disease. A third of patients had developed distant metastases.
- Malignant fibrous histiocytoma and fibrosarcoma accounted for the highest number of histologic varieties.
- FNAC is an effective procedure in the diagnosis of soft tissue tumors.
- Surgery is the prime modality of treatment.
- Post excisional defects were reconstructed with myocutaneous flaps, thereby achieving good cosmetic and functional results.
- Multimodality approach with preoperative radiotherapy and post-operative chemotherapy is the standard in the management of sarcomas.

#### **Discussion**

For many years, the treatment of soft tissue sarcomas has continued to pose significant challenges. It is due to relative rarity of these tumors, contributed to by lack of proper understanding of their biological behavior and a significant delay in the diagnosis. The past decade has seen a dramatic increase in the adoption of multiple modality therapy for these tumors with a

significant reduction in the number of amputations performed for extremity lesions. An effort to decrease local recurrence of extremity sarcomas has been successful. Multimodality approach offers the potential for improved local control with less radical operations.

It is evident from this prospective study that most patients resented very late in the course of illness. Significant delay in diagnosis only contributes to the aggressive behavior of these tumors. About 30- 40% of tumors were treated in the form of incision and drainage, excision and like procedures. Out of 43 patients with soft tissue sarcoma 11 patients were 3gnosed by biopsy to have malignant fibrous histiocytoma.

#### Conclusion

Soft tissue sarcomas constitute a significant challenge to the surgeon. They are rare tumours accounting for 1% of all malignancies, and there are more than 20 histologic varieties each with varying biologic behavior and a propensity for early metastatic spread. They are aggressive neoplasms. They are very innocent looking at the initial stages of the disease and relatively symptomless. This probably makes the patients very complacent towards the existence of the tumour and by the time they present, it is already in an advanced stage. To compound to the problem of late diagnosis, the problem of indifferent treatment in the peripheral set up. Multimodality approach is the current standard for the treatment of sarcomas. With majority of tumours presenting in the extremities, the aim of surgery in most situations is limb salvage. Radiotherapy has been convincingly proved to be an effective tool in the treatment armamentarium for soft tissue sarcomas. Chemotherapy has been reserved for metastatic disease although a few selected trials have established the usefulness of pre-operative chemotherapy in multimodal approach. Doxorubicin and Ifosfamide are the two drugs with promise in the field of managing advanced sarcomas.

Molecular biology has promise for the future. The focus on genetic alterations that predispose to

## JMSCR Vol||06||Issue||03||Page1256-1259||March

tumour development and progression, has thrown more light on the etiology of these tumours. The relevance of such genetic abnormalities in diagnosis is obvious, but they have yet to be exploited in terms of clinical management. Soft tissue sarcoma remains an ideal model for the investigation of strategies designed to prove long term outcome. Advances in knowledge of etiological predisposition continue to be de. Multiple prognostic factors are being defined and the disease process is varied enough to vide a fertile field for treatment strategies.

#### References

- 1. Ackerman, L.V., and Rosa, J. The tholo of turnours CA 2 1:368, 1971
- Antman KH. Montella D Roendaun C Schwen M.phase 11 trial of ifosfamide with mesna in previously trtmeta\_claic sarcoma Cancer Treat Rep. 1985: 69.499-502.
- 3. British Journal of Surgery May 2012
- 4. Bowden L. Booher RI The Principles and Techniques of Resection of soft parts for sarcoma surgery
- 5. Brennan MF. Frnch C Almadrones L. et al. Prospective randomized trial examining the cardi. city of adiuvant doxorubicin in high grade extremity sarcomas. In Sydneimon adjuvant therapy of cancer V. Orlando Grune& Stratton. 1987: 745-754
- 6. Eilber, F.R. Morton, D.L., Eckardt.J Grant T. and Weisunburger T., Limb salvage for skeletal and soft tissue *sarcomas* Multidisciplinary preoperative therapy cancer *53*:2579,1984
- 7. European Journal of Surgical Oncology 1993 Dec. 19(6): 641-5
- 8. Eur-J-Sur-Oncol. 1996 April 22 (2): 1446
- 9. Enneking W.F; Spanier S.S; Malaner M.M; The effect of anatomic setting on the results of surgical procedures for soft part sarcoma of the thigh; cancer 47; 1005,1981
- 10. Enzinger. F.M. Soft tissue tumour pathology

- 11. Evans H.L., Study of 59 cases and reassessment of classification.
- 12. Fine G.Hadu. SiMorton DL., et al: Soft tissue sarcomas; classification and treatment; pathology Ann. 17:155,1982
- 13. Fortner. J.G; Kim D.K.Shivine H; Limb preservation Vascular surgery for malignancy of lower extremity
- 14. Presant CA. Lowenbraun S. Bartiolucci AA et a! Metastatic sarcomas Chemotherapy with Adriamyein cyclophosphamide, and methortrexate alternating with actinomycin D.DTIC and vinenstine, Cancer 198 1;47:457-465
- 15. Presgrave P.Wos RL. Tatteresall MH. et a! Combination chemotherapy of adult soft tissue sarcomas with a combination of doxoruhicin and methotrexate. Cancer Treat Rep. 1987; 7 1:1089-1088.
- 16. Rosenberg SA. Tepper J. Glatstein E.et.al. Prospective randomize devaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities cancer 1983; 52; 424-434.
- 17. Rosenberg SA.Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tsue sarcomas. Cancer Treat Rep. 1984; 68:1067-1078.
- 18. Rosenberg SA. Chang. AE. Glasterin E. Adjuvant Chemotherapy for treatment of extremity soft tissue sarcomas: Review of National Cancer Institute experience. Cancer Treat Symp 1985; 3: 83-88.